Oral Semaglutide: Weight Loss Results and Side Effects of the Wegovy Pill

Oral semaglutide for weight loss yields an average reduction of 16,6% over 64 weeks according to the OASIS-4 clinical trial, intensifying clinical discussions about needle-free options for obesity management. While the U.S. Food and Drug Administration approved the oral tablet format in December 2025, health authorities in Germany have scheduled a market entry for September 2026 under strict eligibility requirements.

Clinical Efficacy and Trial Results

According to the OASIS-4 study data, participants taking the oral formulation achieved an average weight loss of 16,6% after 64 weeks of treatment, compared to a 2,7% reduction in the control group. Broader context from a meta-analysis encompassing 15 randomized trials and more than 14,000 participants shows that efficacy profiles vary significantly across different active ingredients and delivery mechanisms within the class of GLP-1 receptor agonists.

When evaluated alongside injectable alternatives, dosing strength heavily influences overall performance. Tirzepatid leads comparative efficacy analyses with a weight reduction exceeding 20% at its highest dose. Injectable semaglutide delivers approximately 15% weight loss, while liraglutide reaches around 8%. The 50-mg oral semaglutide dose outperforms liraglutide and low-dose tirzepatid, though clinical follow-ups indicate that patients regain roughly two thirds of lost weight within one year after stopping the medication.

Daily Administration and Strict Dosing Rules

Pharmacokinetic requirements dictate a precise daily routine to ensure proper drug absorption. Patients must take the tablet on an empty stomach accompanied by a maximum of 120 ml of water. Medical protocols mandate a strict 30-minute window of fasting from food and liquids following ingestion to prevent interference with systemic uptake.

Side Effects and Treatment Discontinuation

Gastrointestinal side effects present a notable challenge for daily adherence, with clinical trials recording a 74% incidence rate of stomach-related complaints among users. Approximately 7% of trial participants discontinued treatment early due to adverse events. Real-world utilization data from the United Kingdom reflects cautious patient uptake, where only 6% of existing users transitioned from injections to the oral tablet despite established treatment routines.

Pricing and Market Access

Monthly treatment costs vary by region and formulation. In the United States, monthly expenses for the oral tablet range from $149 to $299 based on dosage, whereas the injectable version costs $349. In the United Kingdom, introductory pricing stands at approximately £99 for the starter dose, compared to £79.97 for injections, with standard monthly doses projected at £134.

For patients in Germany, statutory health insurance funds will not cover the cost of the medication despite the anticipated September 2026 launch. Regulatory access remains strictly confined to individuals with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher in the presence of at least one weight-related comorbid condition.